創薬における標的の検証 Target Validation in Drug Discovery

Metcalf, Brian W.(EDT)/ Dillon, Susan(EDT)

Academic Press（2006/09発売）

• 製本 Hardcover:ハードカバー版／ページ数 296 p.
• 言語 ENG
• 商品コード 9780123693938
• DDC分類 615.19

基本説明

Begins with a detailed descriptions of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin, and more.

Full Description

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book.

Contents

III: Target validation for biopharmaceutical drug discoveryChapter 3: CETUXIMAB (ERBITUX (R)), AN ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR Chapter 6: ANTI-CCL-2/MCP-1: DIRECTED BIOLOGICALS FOR INFLAMMATORY AND MALIGNANT DISEASESChapter 7: TARGETING IL-12P40 FOR IMMUNE-MEDIATED DISEASEChapter 8: THE GPIIB/IIIA ANTAGONIST ABCIXIMAB FOR ACUTE PERCUTANEOUS CORONARY INTERVENTIONIII: Validating targets of small molecule approachesChapter 9: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: INHIBITORSChapter 11: IKK-2/NF- B-DEPENDENT TRANSCRIPTIONChapter 12: TNF SIGNALING PATHWAY INHIBITORS FOR INFLAMMATION-CCR2 ANTAGONISTSAGONISTChapter 14: ORALLY BIOAVAILABLE GLYCOPROTEIN IIB/IIIA ANTAGONISTS: A NEGATIVE CASE STUDYINDEX